Repligen is pleased to announce that it has appointed Jonathan I. Lieber as its CFO and Treasurer, effective immediately. He will be responsible for leading Repligen's financial activities, including long-term financial strategy and risk management. Repligen's current CFO William J. Kelly will now serve as the company's Chief Accounting Officer, overseeing Repligen's internal controls and its accounting and management reporting functions.
In connection with Mr. Lieber's appointment, the company granted him an inducement equity award outside of Repligen's 2012 Stock Option and Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The award is for 15,000 shares of restricted stock which will vest in full on the first anniversary of Mr. Lieber's start date.
"We are pleased to welcome Jonathan Lieber to the CFO role," said Walter C. Herlihy, Ph.D., President and Chief Executive Officer at Repligen. "Over the past nine months, Repligen has become a profitable, significantly larger and more complex multinational organization. As the Company enters its next phase of growth, Mr. Lieber brings a particularly relevant skill set to the management team. His combined life sciences and capital markets expertise will be major assets to the Company as we advance on our strategy to further expand Repligen's bioprocessing business and deliver top-tier financial performance."
Most recently, Mr. Lieber was the CFO and Treasurer at Xcellerex, Inc., a supplier of bioprocessing products and disposable biomanufacturing technologies. Mr. Lieber led the company's accounting, finance, legal, and corporate communications activities. He restructured the finance department and implemented business processes to support substantial revenue growth. Prior to Xcellerex, Mr. Lieber was with Altus Pharmaceuticals for seven years, most recently as Senior Vice President, CFO, and Treasurer. At Altus, he led all capital raising activities, resulting in net proceeds of $250 million, including its $110 million initial public offering.
Mr. Lieber has been involved in healthcare financings totaling over $3 billion in common stock and over $500 million in initial public offerings. He received a B.S. in business administration and finance from Boston University and an M.B.A. in finance from New York University Stern School of Business.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net